Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
Molecular Cancer
Published in: Molecular Cancer 1/2013

Open Access 01-12-2013 | Review

USP1 deubiquitinase: cellular functions, regulatory mechanisms and emerging potential as target in cancer therapy

Authors: Iraia García-Santisteban, Godefridus J Peters, Elisa Giovannetti, Jose Antonio Rodríguez

Published in: Molecular Cancer | Issue 1/2013

Login to get access

Abstract

Reversible protein ubiquitination is emerging as a key process for maintaining cell homeostasis, and the enzymes that participate in this process, in particular E3 ubiquitin ligases and deubiquitinases (DUBs), are increasingly being regarded as candidates for drug discovery. Human DUBs are a group of approximately 100 proteins, whose cellular functions and regulatory mechanisms remain, with some exceptions, poorly characterized. One of the best-characterized human DUBs is ubiquitin-specific protease 1 (USP1), which plays an important role in the cellular response to DNA damage. USP1 levels, localization and activity are modulated through several mechanisms, including protein-protein interactions, autocleavage/degradation and phosphorylation, ensuring that USP1 function is carried out in a properly regulated spatio-temporal manner. Importantly, USP1 expression is deregulated in certain types of human cancer, suggesting that USP1 could represent a valid target in cancer therapy. This view has gained recent support with the finding that USP1 inhibition may contribute to revert cisplatin resistance in an in vitro model of non-small cell lung cancer (NSCLC). Here, we describe the current knowledge on the cellular functions and regulatory mechanisms of USP1. We also summarize USP1 alterations found in cancer, combining data from the literature and public databases with our own data. Finally, we discuss the emerging potential of USP1 as a target, integrating published data with our novel findings on the effects of the USP1 inhibitor pimozide in combination with cisplatin in NSCLC cells.
Appendix
Available only for authorised users
Literature
1.
Hershko A: Ubiquitin: roles in protein modification and breakdown. Cell. 1983, 34 (1): 11-12. 10.1016/0092-8674(83)90131-9CrossRefPubMed
2.
Chen ZJ, Sun LJ: Nonproteolytic functions of ubiquitin in cell signaling. Mol Cell. 2009, 33 (3): 275-286. 10.1016/j.molcel.2009.01.014CrossRefPubMed
3.
Pickart CM: Mechanisms underlying ubiquitination. Annu Rev Biochem. 2001, 70: 503-533. 10.1146/annurev.biochem.70.1.503CrossRefPubMed
4.
Ikeda F, Dikic I: Atypical ubiquitin chains: new molecular signals, protein modifications: beyond the usual suspects’ review series. EMBO Rep. 2008, 9 (6): 536-542. 10.1038/embor.2008.93PubMedCentralCrossRefPubMed
5.
Kirisako T, Kamei K, Murata S, Kato M, Fukumoto H, Kanie M, Sano S, Tokunaga F, Tanaka K, Iwai K: A ubiquitin ligase complex assembles linear polyubiquitin chains. EMBO J. 2006, 25 (20): 4877-4887. 10.1038/sj.emboj.7601360PubMedCentralCrossRefPubMed
6.
Komander D, Rape M: The ubiquitin code. Annu Rev Biochem. 2012, 81: 203-229. 10.1146/annurev-biochem-060310-170328CrossRefPubMed
7.
Trempe JF: Reading the ubiquitin postal code. Curr Opin Struct Biol. 2011, 21 (6): 792-801. 10.1016/j.sbi.2011.09.009CrossRefPubMed
8.
Kulathu Y, Komander D: Atypical ubiquitylation-the unexplored world of polyubiquitin beyond Lys48 and Lys63 linkages. Nat Rev Mol Cell Biol. 2012, 13 (8): 508-523. 10.1038/nrm3394CrossRefPubMed
9.
Kessler BM: Ubiquitin-omics reveals novel networks and associations with human disease. Curr Opin Chem Biol. 2013, 17 (1): 59-65. 10.1016/j.cbpa.2012.12.024CrossRefPubMed
10.
Reyes-Turcu FE, Ventii KH, Wilkinson KD: Regulation and cellular roles of ubiquitin-specific deubiquitinating enzymes. Annu Rev Biochem. 2009, 78: 363-397. 10.1146/annurev.biochem.78.082307.091526CrossRefPubMed
11.
Edelmann MJ, Iphöfer A, Akutsu M, Altun M, di Gleria K, Kramer HB, Fiebiger E, Dhe-Paganon S, Kessler BM: Structural basis and specificity of human otubain 1-mediated deubiquitination. Biochem J. 2009, 418 (2): 379-390. 10.1042/BJ20081318CrossRefPubMed
12.
Virdee S, Ye Y, Nguyen DP, Komander D, Chin JW: Engineered diubiquitin synthesis reveals Lys29-isopeptide specificity of an OTU deubiquitinase. Nat Chem Biol. 2010, 6 (10): 750-757. 10.1038/nchembio.426CrossRefPubMed
13.
Faesen AC, Luna-Vargas MP, Geurink PP, Clerici M, Merkx R, Van Dijk WJ, Hameed DS, El Oualid F, Ovaa H, Sixma TK: The differential modulation of USP activity by internal regulatory domains, interactors and eight ubiquitin chain types. Chem Biol. 2011, 18 (12): 1550-1561. 10.1016/j.chembiol.2011.10.017CrossRefPubMed
14.
Rivkin E, Almeida SM, Ceccarelli DF, Juang YC, MacLean TA, Srikumar T, Huang H, Dunham WH, Fukumura R, Xie G, Gondo Y, Raught B, Gingras AC, Sicheri F, Cordes SP: The linear ubiquitin-specific deubiquitinase gumby regulates angiogenesis. Nature. 2013, 498 (7454): 318-324. 10.1038/nature12296CrossRefPubMed
15.
Keusekotten K, Elliott PR, Glockner L, Fiil BK, Damgaard RB, Kulathu Y, Wauer T, Hospenthal MK, Gyrd-Hansen M, Krappmann D, Hofmann K, Komander D: OTULIN antagonizes LUBAC signaling by specifically hydrolyzing Met1-linked polyubiquitin. Cell. 2013, 153 (6): 1312-1326. 10.1016/j.cell.2013.05.014PubMedCentralCrossRefPubMed
16.
17.
Nakayama KI, Nakayama K: Ubiquitin ligases: cell-cycle control and cancer. Nat Rev Canc. 2006, 6 (5): 369-381. 10.1038/nrc1881.CrossRef
18.
Vucic D, Dixit VM, Wertz IE: Ubiquitylation in apoptosis: a post-translational modification at the edge of life and death. Nat Rev Mol Cell Biol. 2011, 12 (7): 439-452. 10.1038/nrm3143CrossRefPubMed
19.
Ulrich HD, Walden H: Ubiquitin signalling in DNA replication and repair. Nat Rev Mol Cell Biol. 2010, 11 (7): 479-489. 10.1038/nrm2921CrossRefPubMed
20.
Schaefer A, Nethe M, Hordijk PL: Ubiquitin links to cytoskeletal dynamics, cell adhesion and migration. Biochem J. 2012, 442 (1): 13-25. 10.1042/BJ20111815CrossRefPubMed
21.
Chen D, Frezza M, Schmitt S, Kanwar J, Dou QP: Bortezomib as the first proteasome inhibitor anticancer drug: current status and future perspectives. Curr Canc Drug Targets. 2011, 11 (3): 239-253. 10.2174/156800911794519752.CrossRef
22.
Hoeller D, Dikic I: Targeting the ubiquitin system in cancer therapy. Nature. 2009, 458 (7237): 438-444. 10.1038/nature07960CrossRefPubMed
23.
Mattern MR, Wu J, Nicholson B: Ubiquitin-based anticancer therapy: carpet bombing with proteasome inhibitors vs surgical strikes with E1, E2, E3, or DUB inhibitors. Biochim Biophys Acta. 2012, 1823 (11): 2014-2021. 10.1016/j.bbamcr.2012.05.005CrossRefPubMed
24.
Edelmann MJ, Nicholson B, Kessler BM: Pharmacological targets in the ubiquitin system offer new ways of treating cancer, neurodegenerative disorders and infectious diseases. Expert Rev Mol Med. 2011, 13: e35-PubMedCentralCrossRefPubMed
25.
Fulda S, Rajalingam K, Dikic I: Ubiquitylation in immune disorders and cancer: from molecular mechanisms to therapeutic implications. EMBO Mol Med. 2012, 4 (7): 545-556. 10.1002/emmm.201100707PubMedCentralCrossRefPubMed
26.
D’Arcy P, Linder S: Proteasome deubiquitinases as novel targets for cancer therapy. Int J Biochem Cell Biol. 2012, 44 (11): 1729-1738. 10.1016/j.biocel.2012.07.011CrossRefPubMed
27.
Nijman SM, Luna-Vargas MP, Velds A, Brummelkamp TR, Dirac AM, Sixma TK, Bernards R: A genomic and functional inventory of deubiquitinating enzymes. Cell. 2005, 123 (5): 773-786. 10.1016/j.cell.2005.11.007CrossRefPubMed
28.
Komander D, Clague MJ, Urbé S: Breaking the chains: structure and function of the deubiquitinases. Nat Rev Mol Cell Biol. 2009, 10 (8): 550-563. 10.1038/nrm2731CrossRefPubMed
29.
Fraile JM, Quesada V, Rodríguez D, Freije JM, López-Otín C: Deubiquitinases in cancer: new functions and therapeutic options. Oncogene. 2012, 31 (19): 2373-2388. 10.1038/onc.2011.443CrossRefPubMed
30.
Sacco JJ, Coulson JM, Clague MJ, Urbé S: Emerging roles of deubiquitinases in cancer-associated pathways. IUBMB Life. 2010, 62 (2): 140-157.PubMed
31.
Hussain S, Zhang Y, Galardy PJ: DUBs and cancer: the role of deubiquitinating enzymes as oncogenes, non-oncogenes and tumor suppressors. Cell Cycle. 2009, 8 (11): 1688-1697. 10.4161/cc.8.11.8739CrossRefPubMed
32.
Hock AK, Vigneron AM, Carter S, Ludwig RL, Vousden KH: Regulation of p53 stability and function by the deubiquitinating enzyme USP42. EMBO J. 2011, 30 (24): 4921-4930. 10.1038/emboj.2011.419PubMedCentralCrossRefPubMed
33.
Aggarwal K, Massagué J: Ubiquitin removal in the TGF-β pathway. Nat Cell Biol. 2012, 14 (7): 656-657. 10.1038/ncb2534CrossRefPubMed
34.
Clague MJ, Urbé S: Endocytosis: the DUB version. Trends Cell Biol. 2006, 16 (11): 551-559. 10.1016/j.tcb.2006.09.002CrossRefPubMed
35.
Liu Z, Zanata SM, Kim J, Peterson MA, Di Vizio D, Chirieac LR, Pyne S, Agostini M, Freeman MR, Loda M: The ubiquitin-specific protease USP2a prevents endocytosis-mediated EGFR degradation. Oncogene. 2013, 32 (13): 1660-1669. 10.1038/onc.2012.188CrossRefPubMed
36.
Pareja F, Ferraro DA, Rubin C, Cohen-Dvashi H, Zhang F, Aulmann S, Ben-Chetrit N, Pines G, Navon R, Crosetto N, Köstler W, Carvalho S, Lavi S, Schmitt F, Dikic I, Yakhini Z, Sinn P, Mills GB, Yarden Y: Deubiquitination of EGFR by Cezanne-1 contributes to cancer progression. Oncogene. 2012, 31 (43): 4599-4608. 10.1038/onc.2011.587PubMedCentralCrossRefPubMed
37.
Song MS, Salmena L, Carracedo A, Egia A, Lo-Coco F, Teruya-Feldstein J, Pandolfi PP: The deubiquitinylation and localization of PTEN are regulated by a HAUSP-PML network. Nature. 2008, 455 (7214): 813-817. 10.1038/nature07290PubMedCentralCrossRefPubMed
38.
Yang WL, Jin G, Li CF, Jeong YS, Moten A, Xu D, Feng Z, Chen W, Cai Z, Darnay B, Gu W, Lin HK: Cycles of ubiquitination and deubiquitination critically regulate growth factor-mediated activation of Akt signaling. Sci Signal. 2013, 6 (257): ra3- 10.1126/scisignal.2003197CrossRefPubMed
39.
Zhang L, Zhou F, Drabsch Y, Gao R, Snaar-Jagalska BE, Mickanin C, Huang H, Sheppard KA, Porter JA, Lu CX, Ten Dijke P: USP4 is regulated by AKT phosphorylation and directly deubiquitylates TGF-β type I receptor. Nat Cell Biol. 2012, 14 (7): 717-726. 10.1038/ncb2522CrossRefPubMed
40.
Jackson SP, Durocher D: Regulation of DNA damage responses by Ubiquitin and SUMO. Mol Cell. 2013, 49 (5): 795-807. 10.1016/j.molcel.2013.01.017CrossRefPubMed
41.
Colland F: The therapeutic potential of deubiquitinating enzyme inhibitors. Biochem Soc Trans. 2010, 38 (Pt 1): 137-143.CrossRefPubMed
42.
Altun M, Kramer HB, Willems LI, McDermott JL, Leach CA, Goldenberg SJ, Kumar KG, Konietzny R, Fischer R, Kogan E, Mackeen MM, McGouran J, Khoronenkova SV, Parsons JL, Dianov GL, Nicholson B, Kessler BM: Activity-based chemical proteomics accelerates inhibitor development for deubiquitylating enzymes. Chem Biol. 2011, 18 (11): 1401-1412. 10.1016/j.chembiol.2011.08.018CrossRefPubMed
43.
Kapuria V, Peterson LF, Fang D, Bornmann WG, Talpaz M, Donato NJ: Deubiquitinase inhibition by small-molecule WP1130 triggers aggresome formation and tumor cell apoptosis. Canc Res. 2010, 70 (22): 9265-9276. 10.1158/0008-5472.CAN-10-1530.CrossRef
44.
D’Arcy P, Brnjic S, Olofsson MH, Fryknäs M, Lindsten K, De Cesare M, Perego P, Sadeghi B, Hassan M, Larsson R, Linder S: Inhibition of proteasome deubiquitinating activity as a new cancer therapy. Nat Med. 2011, 17 (12): 1636-1640. 10.1038/nm.2536CrossRefPubMed
45.
Ohayon S, Spasser L, Aharoni A, Brik A: Targeting deubiquitinases enabled by chemical synthesis of proteins. J Am Chem Soc. 2012, 134 (6): 3281-3289. 10.1021/ja2116712CrossRefPubMed
46.
Ernst A, Avvakumov G, Tong J, Fan Y, Zhao Y, Alberts P, Persaud A, Walker JR, Neculai AM, Neculai D, Vorobyov A, Garg P, Beatty L, Chan PK, Juang YC, Landry MC, Yeh C, Zeqiraj E, Karamboulas K, Allali-Hassani A, Vedadi M, Tyers M, Moffat J, Sicheri F, Pelletier L, Durocher D, Raught B, Rotin D, Yang J, Moran MF, Dhe-Paganon S, Sidhu SS: A strategy for modulation of enzymes in the ubiquitin system. Science. 2013, 339 (6119): 590-595. 10.1126/science.1230161CrossRefPubMed
47.
Bouwman P, Jonkers J: The effects of deregulated DNA damage signalling on cancer chemotherapy response and resistance. Nat Rev Canc. 2012, 12 (9): 587-598. 10.1038/nrc3342.CrossRef
48.
Curtin NJ: DNA repair dysregulation from cancer driver to therapeutic target. Nat Rev Canc. 2012, 12 (12): 801-817. 10.1038/nrc3399.CrossRef
49.
Hofmann K: Ubiquitin-binding domains and their role in the DNA damage response. DNA Repair (Amst). 2009, 8 (4): 544-556. 10.1016/j.dnarep.2009.01.003.CrossRef
50.
Kirchmaier AL: Ub-family modifications at the replication fork: regulating PCNA-interacting components. FEBS Lett. 2011, 585 (18): 2920-2928. 10.1016/j.febslet.2011.08.008CrossRefPubMed
51.
Kim H, D’Andrea AD: Regulation of DNA cross-link repair by the Fanconi anemia/BRCA pathway. Genes Dev. 2012, 26 (13): 1393-1408. 10.1101/gad.195248.112PubMedCentralCrossRefPubMed
52.
Fujiwara T, Saito A, Suzuki M, Shinomiya H, Suzuki T, Takahashi E, Tanigami A, Ichiyama A, Chung CH, Nakamura Y, Tanaka K: Identification and chromosomal assignment of USP1, a novel gene encoding a human ubiquitin-specific protease. Genomics. 1998, 54 (1): 155-158. 10.1006/geno.1998.5554CrossRefPubMed
53.
Villamil MA, Chen J, Liang Q, Zhuang Z: A noncanonical cysteine protease USP1 is activated through active site modulation by USP1-associated factor 1. Biochemistry. 2012, 51 (13): 2829-2839. 10.1021/bi3000512CrossRefPubMed
54.
Békés M, Huang T: Ubiquitin-specific peptidase 1. Handbook of proteolytic enzymes. Volume 1. Edited by: Rawlings ND, Salvesen G. 2013, 2079-2085. 3,CrossRef
55.
Nijman SM, Huang TT, Dirac AM, Brummelkamp TR, Kerkhoven RM, D’Andrea AD, Bernards R: The deubiquitinating enzyme USP1 regulates the Fanconi anemia pathway. Mol Cell. 2005, 17 (3): 331-339. 10.1016/j.molcel.2005.01.008CrossRefPubMed
56.
Huang TT, Nijman SM, Mirchandani KD, Galardy PJ, Cohn MA, Haas W, Gygi SP, Ploegh HL, Bernards R, D’Andrea AD: Regulation of monoubiquitinated PCNA by DUB autocleavage. Nat Cell Biol. 2006, 8 (4): 339-347.CrossRefPubMed
57.
Williams SA, Maecker HL, French DM, Liu J, Gregg A, Silverstein LB, Cao TC, Carano RA, Dixit VM: USP1 deubiquitinates ID proteins to preserve a mesenchymal stem cell program in osteosarcoma. Cell. 2011, 146 (6): 918-930. 10.1016/j.cell.2011.07.040CrossRefPubMed
58.
Cohn MA, Kowal P, Yang K, Haas W, Huang TT, Gygi SP, D’Andrea AD: A UAF1-containing multisubunit protein complex regulates the Fanconi anemia pathway. Mol Cell. 2007, 28 (5): 786-797. 10.1016/j.molcel.2007.09.031CrossRefPubMed
59.
60.
Sims AE, Spiteri E, Sims RJ, Arita AG, Lach FP, Landers T, Wurm M, Freund M, Neveling K, Hanenberg H, Auerbach AD, Huang TT: FANCI is a second monoubiquitinated member of the Fanconi anemia pathway. Nat Struct Mol Biol. 2007, 14 (6): 564-567. 10.1038/nsmb1252CrossRefPubMed
61.
Parmar K, Kim J, Sykes SM, Shimamura A, Stuckert P, Zhu K, Hamilton A, Deloach MK, Kutok JL, Akashi K, Gilliland DG, D’andrea A: Hematopoietic stem cell defects in mice with deficiency of Fancd2 or Usp1. Stem Cells. 2010, 28 (7): 1186-1195. 10.1002/stem.437PubMedCentralCrossRefPubMed
62.
Oestergaard VH, Langevin F, Kuiken HJ, Pace P, Niedzwiedz W, Simpson LJ, Ohzeki M, Takata M, Sale JE, Patel KJ: Deubiquitination of FANCD2 is required for DNA crosslink repair. Mol Cell. 2007, 28 (5): 798-809. 10.1016/j.molcel.2007.09.020PubMedCentralCrossRefPubMed
63.
Kim JM, Parmar K, Huang M, Weinstock DM, Ruit CA, Kutok JL, D’Andrea AD: Inactivation of murine Usp1 results in genomic instability and a Fanconi anemia phenotype. Dev Cell. 2009, 16 (2): 314-320. 10.1016/j.devcel.2009.01.001PubMedCentralCrossRefPubMed
64.
Murai J, Yang K, Dejsuphong D, Hirota K, Takeda S, D’Andrea AD: The USP1/UAF1 complex promotes double-strand break repair through homologous recombination. Mol Cell Biol. 2011, 31 (12): 2462-2469. 10.1128/MCB.05058-11PubMedCentralCrossRefPubMed
65.
Hoege C, Pfander B, Moldovan GL, Pyrowolakis G, Jentsch S: RAD6-dependent DNA repair is linked to modification of PCNA by ubiquitin and SUMO. Nature. 2002, 419 (6903): 135-141. 10.1038/nature00991CrossRefPubMed
66.
Friedberg EC, Lehmann AR, Fuchs RP: Trading places: how do DNA polymerases switch during translesion DNA synthesis?. Mol Cell. 2005, 18 (5): 499-505. 10.1016/j.molcel.2005.03.032CrossRefPubMed
67.
Terai K, Abbas T, Jazaeri AA, Dutta A: CRL4Cdt2 E3 ubiquitin ligase monoubiquitinates PCNA to promote translesion DNA synthesis. Mol Cell. 2010, 37 (1): 143-149. 10.1016/j.molcel.2009.12.018PubMedCentralCrossRefPubMed
68.
Jones MJ, Colnaghi L, Huang TT: Dysregulation of DNA polymerase κ recruitment to replication forks results in genomic instability. EMBO J. 2012, 31 (4): 908-918.PubMedCentralCrossRefPubMed
69.
Yokota Y, Mori S: Role of Id family proteins in growth control. J Cell Physiol. 2002, 190 (1): 21-28. 10.1002/jcp.10042CrossRefPubMed
70.
Perk J, Iavarone A, Benezra R: Id family of helix-loop-helix proteins in cancer. Nat Rev Canc. 2005, 5 (8): 603-614. 10.1038/nrc1673.CrossRef
71.
Cotto-Rios XM, Jones MJ, Busino L, Pagano M, Huang TT: APC/CCdh1-dependent proteolysis of USP1 regulates the response to UV-mediated DNA damage. J Cell Biol. 2011, 194 (2): 177-186. 10.1083/jcb.201101062PubMedCentralCrossRefPubMed
72.
Cataldo F, Peche LY, Klaric E, Brancolini C, Myers MP, Demarchi F, Schneider C: CAPNS1 Regulates USP1 Stability and the Maintenance of Genome Integrity. Mol Cell Biol. 2013, 33 (12): 2485-2496. 10.1128/MCB.01406-12PubMedCentralCrossRefPubMed
73.
Garcia-Santisteban I, Zorroza K, Rodriguez JA: Two nuclear localization signals in USP1 mediate nuclear import of the USP1/UAF1 complex. PLoS One. 2012, 7 (6): e38570- 10.1371/journal.pone.0038570PubMedCentralCrossRefPubMed
74.
Villamil MA, Liang Q, Chen J, Choi YS, Hou S, Lee KH, Zhuang Z: Serine phosphorylation is critical for the activation of ubiquitin-specific protease 1 and its interaction with WD40-repeat protein UAF1. Biochemistry. 2012, 51 (45): 9112-9123. 10.1021/bi300845sPubMedCentralCrossRefPubMed
75.
Cohn MA, Kee Y, Haas W, Gygi SP, D’Andrea AD: UAF1 is a subunit of multiple deubiquitinating enzyme complexes. J Biol Chem. 2009, 284 (8): 5343-5351.PubMedCentralCrossRefPubMed
76.
Yang K, Moldovan GL, Vinciguerra P, Murai J, Takeda S, D’Andrea AD: Regulation of the Fanconi anemia pathway by a SUMO-like delivery network. Genes Dev. 2011, 25 (17): 1847-1858. 10.1101/gad.17020911PubMedCentralCrossRefPubMed
77.
Lee KY, Yang K, Cohn MA, Sikdar N, D’Andrea AD, Myung K: Human ELG1 regulates the level of ubiquitinated proliferating cell nuclear antigen (PCNA) through its interactions with PCNA and USP1. J Biol Chem. 2010, 285 (14): 10362-10369. 10.1074/jbc.M109.092544PubMedCentralCrossRefPubMed
78.
García-Santisteban I, Bañuelos S, Rodríguez JA: A global survey of CRM1-dependent nuclear export sequences in the human deubiquitinase family. Biochem J. 2012, 441 (1): 209-217. 10.1042/BJ20111300CrossRefPubMed
79.
Rego MA, Harney JA, Mauro M, Shen M, Howlett NG: Regulation of the activation of the Fanconi anemia pathway by the p21 cyclin-dependent kinase inhibitor. Oncogene. 2012, 31 (3): 366-375. 10.1038/onc.2011.237PubMedCentralCrossRefPubMed
80.
Piatkov KI, Colnaghi L, Békés M, Varshavsky A, Huang TT: The auto-generated fragment of the Usp1 deubiquitylase is a physiological substrate of the N-end rule pathway. Mol Cell. 2012, 48 (6): 926-933. 10.1016/j.molcel.2012.10.012PubMedCentralCrossRefPubMed
81.
Cotto-Rios XM, Békés M, Chapman J, Ueberheide B, Huang TT: Deubiquitinases as a signaling target of oxidative stress. Cell Rep. 2012, 2 (6): 1475-1484. 10.1016/j.celrep.2012.11.011PubMedCentralCrossRefPubMed
82.
Lee JG, Baek K, Soetandyo N, Ye Y: Reversible inactivation of deubiquitinases by reactive oxygen species in vitro and in cells. Nat Commun. 2013, 4: 1568-PubMedCentralCrossRefPubMed
83.
Kulathu Y, Garcia FJ, Mevissen TE, Busch M, Arnaudo N, Carroll KS, Barford D, Komander D: Regulation of A20 and other OTU deubiquitinases by reversible oxidation. Nat Commun. 2013, 4: 1569-PubMedCentralCrossRefPubMed
84.
Cotto-Rios XM, Jones MJ, Huang TT: Insights into phosphorylation-dependent mechanisms regulating USP1 protein stability during the cell cycle. Cell Cycle. 2011, 10 (23): 4009-4016. 10.4161/cc.10.23.18501PubMedCentralCrossRefPubMed
85.
Bignell GR, Warren W, Seal S, Takahashi M, Rapley E, Barfoot R, Green H, Brown C, Biggs PJ, Lakhani SR, Jones C, Hansen J, Blair E, Hofmann B, Siebert R, Turner G, Evans DG, Schrander-Stumpel C, Beemer FA, van Den Ouweland A, Halley D, Delpech B, Cleveland MG, Leigh I, Leisti J, Rasmussen S: Identification of the familial cylindromatosis tumour-suppressor gene. Nat Genet. 2000, 25 (2): 160-165. 10.1038/76006CrossRefPubMed
86.
87.
88.
Toffalorio F, Giovannetti E, De Pas T, Radice D, Pelosi G, Manzotti M, Minocci D, Spaggiari L, Spitaleri G, Noberasco C, Catania C, Boselli S, Danesi R, De Braud F: Expression of gemcitabine- and cisplatin-related genes in non-small-cell lung cancer. Pharmacogenomics J. 2010, 10 (3): 180-190. 10.1038/tpj.2009.53CrossRefPubMed
89.
Luise C, Capra M, Donzelli M, Mazzarol G, Jodice MG, Nuciforo P, Viale G, Di Fiore PP, Confalonieri S: An atlas of altered expression of deubiquitinating enzymes in human cancer. PLoS One. 2011, 6 (1): e15891- 10.1371/journal.pone.0015891PubMedCentralCrossRefPubMed
90.
91.
Liu Y, Luo X, Hu H, Wang R, Sun Y, Zeng R, Chen H: Integrative proteomics and tissue microarray profiling indicate the association between overexpressed serum proteins and non-small cell lung cancer. PLoS One. 2012, 7 (12): e51748- 10.1371/journal.pone.0051748PubMedCentralCrossRefPubMed
92.
Zhiqiang Z, Qinghui Y, Yongqiang Z, Jian Z, Xin Z, Haiying M, Yuepeng G: USP1 regulates AKT phosphorylation by modulating the stability of PHLPP1 in lung cancer cells. J Canc Res Clin Oncol. 2012, 138 (7): 1231-1238. 10.1007/s00432-012-1193-3. 10.1007/s00432-012-1193-3CrossRef
93.
Galluzzi L, Senovilla L, Vitale I, Michels J, Martins I, Kepp O, Castedo M, Kroemer G: Molecular mechanisms of cisplatin resistance. Oncogene. 2012, 31 (15): 1869-1883. 10.1038/onc.2011.384CrossRefPubMed
94.
Chen J, Dexheimer TS, Ai Y, Liang Q, Villamil MA, Inglese J, Maloney DJ, Jadhav A, Simeonov A, Zhuang Z: Selective and cell-active inhibitors of the USP1/UAF1 deubiquitinase complex reverse cisplatin resistance in non-small cell lung cancer cells. Chem Biol. 2011, 18 (11): 1390-1400. 10.1016/j.chembiol.2011.08.014PubMedCentralCrossRefPubMed
95.
Chou TC, Talalay P: Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors. Adv Enzyme Regul. 1984, 22: 27-55.CrossRefPubMed
96.
Bijnsdorp IV, Giovannetti E, Peters GJ: Analysis of drug interactions. Meth Mol Biol. 2011, 731: 421-434. 10.1007/978-1-61779-080-5_34.CrossRef
97.
Skehan P, Storeng R, Scudiero D, Monks A, McMahon J, Vistica D, Warren JT, Bokesch H, Kenney S, Boyd MR: New colorimetric cytotoxicity assay for anticancer-drug screening. J Natl Canc Inst. 1990, 82 (13): 1107-1112. 10.1093/jnci/82.13.1107.CrossRef
98.
Sowa ME, Bennett EJ, Gygi SP, Harper JW: Defining the human deubiquitinating enzyme interaction landscape. Cell. 2009, 138 (2): 389-403. 10.1016/j.cell.2009.04.042PubMedCentralCrossRefPubMed
Metadata
Title
USP1 deubiquitinase: cellular functions, regulatory mechanisms and emerging potential as target in cancer therapy
Authors
Iraia García-Santisteban
Godefridus J Peters
Elisa Giovannetti
Jose Antonio Rodríguez
Publication date
01-12-2013
Publisher
BioMed Central
Published in
Molecular Cancer / Issue 1/2013
Electronic ISSN: 1476-4598
DOI
https://doi.org/10.1186/1476-4598-12-91

Other articles of this Issue 1/2013

Molecular Cancer 1/2013 Go to the issue

Research

TMEM16A alternative splicing coordination in breast cancer

Research

Epigenetic reactivation of estrogen receptor-α (ERα) by genistein enhances hormonal therapy sensitivity in ERα-negative breast cancer

Research

Promoting effect of neutrophils on lung tumorigenesis is mediated by CXCR2 and neutrophil elastase

Research

Inhibition of clathrin by pitstop 2 activates the spindle assembly checkpoint and induces cell death in dividing HeLa cancer cells

Research

Role of moesin in hyaluronan induced cell migration in glioblastoma multiforme

Research

Combination treatment with ABT-737 and chloroquine in preclinical models of small cell lung cancer
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits